Immunyx is a drug development company focused on neutrophil modulation in disease.
Neutrophils are the most populous immune cell, yet few advances have been made in modulating their disease-causing activity.
Large pharma is working on neutrophil therapies such as Danirixin and Navarixin.
Currently there are no FDA approved neutrophil therapies due to Neutropenia, systemic toxicity and difficulty reaching neutrophils at target location.
Effective and safe treatments to prevent deregulated neutrophil damage in numerous large market diseases.
Neutrophil modulation via targeted delivery.